{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:18:56Z","timestamp":1787019536536,"version":"build-2736575974"},"reference-count":34,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To evaluate the prognostic impact of minimal residual disease (MRD), quantitative real-time polymerase chain reaction (RQ-PCR) of clonal IGH rearrangements was performed in 29 patients with mantle cell lymphoma (MCL) treated with high-dose radiochemotherapy and autologous stem cell transplantation (ASCT). Fourteen of 27 patients evaluable for MRD after ASCT achieved complete clinical and molecular remission, whereas 13 patients had detectable MRD within the first year after ASCT. Molecular remission after ASCT was strongly predictive for improved outcome, with a median progression-free survival (PFS) of 92 months in the MRD-negative group compared with 21 months in the MRD-positive group (P &lt; .001). Median overall survival (OS) was 44 months in the MRD-positive group and has not been reached in the MRD-negative group (P &lt; .003). In multivariate analysis, molecular remission and bulky disease were independent prognostic factors for PFS (P = .001 and P = .021, respectively). While cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP)\u2013like cytoreduction had only modest influence, ara-C\u2013containing mobilization and myeloablative radiochemotherapy significantly reduced MRD. Quantitative MRD measured in the stem cell products of 27 patients was not predictive for molecular remission. We conclude that sequential quantitative monitoring of residual disease after ASCT is a powerful indicator for treatment outcome in MCL and defines subgroups of patients with a significantly different prognosis.<\/jats:p>","DOI":"10.1182\/blood-2005-07-2845","type":"journal-article","created":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T22:13:44Z","timestamp":1133907224000},"page":"2271-2278","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":132,"title":["Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma"],"prefix":"10.1182","volume":"107","author":[{"given":"Christiane","family":"Pott","sequence":"first","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schrader","sequence":"additional","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gesk","sequence":"additional","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Harder","sequence":"additional","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Tiemann","sequence":"additional","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Raff","sequence":"additional","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Bru\u0308ggemann","sequence":"additional","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ritgen","sequence":"additional","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Gahn","sequence":"additional","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Unterhalt","sequence":"additional","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Siebert","sequence":"additional","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kneba","sequence":"additional","affiliation":[{"name":"From the Second Medical Department, Institute of Human Genetics, Institute of Hematopathology, University Hospital Schleswig-Holstein, Campus Kiel; Department of Internal Medicine III, University of Munich, Grosshadern; Department of Medicine V, University of Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111711032620100_REF1","doi-asserted-by":"crossref","unstructured":"Meusers P, Engelhard M, Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol.1989;7: 365-380.","DOI":"10.1002\/hon.2900070505"},{"key":"2019111711032620100_REF2","doi-asserted-by":"crossref","unstructured":"Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood.1997;89: 2067-2078.","DOI":"10.1182\/blood.V89.6.2067"},{"key":"2019111711032620100_REF3","doi-asserted-by":"crossref","unstructured":"Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol.2002;20: 1288-1294.","DOI":"10.1200\/JCO.2002.20.5.1288"},{"key":"2019111711032620100_REF4","doi-asserted-by":"crossref","unstructured":"Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol.2005;23: 1984-1992.","DOI":"10.1200\/JCO.2005.08.133"},{"key":"2019111711032620100_REF5","doi-asserted-by":"crossref","unstructured":"Andersen NS, Pedersen L, Elonen E, et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol.2003;71: 73-80.","DOI":"10.1034\/j.1600-0609.2003.00093.x"},{"key":"2019111711032620100_","doi-asserted-by":"crossref","unstructured":"Kroger N, Hoffknecht M, Dreger P, et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant.1998;21: 55-57.","DOI":"10.1038\/sj.bmt.1701033"},{"key":"2019111711032620100_REF7","doi-asserted-by":"crossref","unstructured":"Dreger P, Martin S, Kuse R, et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J.2000;1: 87-94.","DOI":"10.1038\/sj.thj.6200007"},{"key":"2019111711032620100_REF8","doi-asserted-by":"crossref","unstructured":"Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma: results of a prospective randomized trial of the European MCL network. Blood.2005;105: 2677-2684.","DOI":"10.1182\/blood-2004-10-3883"},{"key":"2019111711032620100_REF9","doi-asserted-by":"crossref","unstructured":"Vandenberghe E, Ruiz de Elvira C, Loberiza FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol.2003;120: 793-800.","DOI":"10.1046\/j.1365-2141.2003.04140.x"},{"key":"2019111711032620100_REF10","doi-asserted-by":"crossref","unstructured":"Andersen NS, Donovan JW, Borus JS, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood.1997;90: 4212-4221.","DOI":"10.1182\/blood.V90.10.4212"},{"key":"2019111711032620100_REF11","doi-asserted-by":"crossref","unstructured":"Corradini P, Astolfi M, Cherasco C, et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood.1997;89: 724-731.","DOI":"10.1182\/blood.V89.2.724"},{"key":"2019111711032620100_REF12","doi-asserted-by":"crossref","unstructured":"Corradini P, Ladetto M, Zallio F, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol.2004;22: 1460-1468.","DOI":"10.1200\/JCO.2004.10.054"},{"key":"2019111711032620100_REF13","doi-asserted-by":"crossref","unstructured":"Ritgen M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood.2004;104: 2600-2602.","DOI":"10.1182\/blood-2003-12-4321"},{"key":"2019111711032620100_REF14","doi-asserted-by":"crossref","unstructured":"Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant.2003;32: 1159-1163.","DOI":"10.1038\/sj.bmt.1704290"},{"key":"2019111711032620100_REF15","doi-asserted-by":"crossref","unstructured":"Kurokawa T, Kinoshita T, Murate T, et al. Complementarity determining region-III is a useful molecular marker for the evaluation of minimal residual disease in mantle cell lymphoma. Br J Haematol.1997;98: 408-412.","DOI":"10.1046\/j.1365-2141.1997.2133030.x"},{"key":"2019111711032620100_REF16","doi-asserted-by":"crossref","unstructured":"Pott C, Tiemann M, Linke B, et al. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Leukemia.1998;12: 1630-1637.","DOI":"10.1038\/sj.leu.2401172"},{"key":"2019111711032620100_REF17","doi-asserted-by":"crossref","unstructured":"Andersen NS, Donovan JW, Zuckerman A, Pedersen L, Geisler C, Gribben JG. Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1\/JH rearrangements in mantle cell lymphoma. Exp Hematol2002;30: 703-710.","DOI":"10.1016\/S0301-472X(02)00807-X"},{"key":"2019111711032620100_REF18","unstructured":"Seyfarth B, Boehme V, Stuhlmann R, et al. Addition of rituximab to TBI\/CY improves outcome of first-line autologous stem cell transplantation for mantle cell lymphoma [abstract]. Bone Marrow Transplant.2004;33(suppl 1): 105."},{"key":"2019111711032620100_REF19","doi-asserted-by":"crossref","unstructured":"Dreger P, Viehmann K, von Neuhoff N, et al. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery. Bone Marrow Transplant.1999;24: 153-161.","DOI":"10.1038\/sj.bmt.1701862"},{"key":"2019111711032620100_REF20","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. J Clin Oncol.1999;17: 3835-3849.","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"2019111711032620100_REF21","doi-asserted-by":"crossref","unstructured":"Zucca E, Stein H, Coiffier B. European Lymphoma Task Force (ELTF): report of the Workshop on Mantle Cell Lymphoma (MCL) [see comments]. Ann Oncol.1994;5: 507-511.","DOI":"10.1093\/oxfordjournals.annonc.a058904"},{"key":"2019111711032620100_REF22","doi-asserted-by":"crossref","unstructured":"van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98\u20133936. Leukemia.2003;17: 2257-2317.","DOI":"10.1038\/sj.leu.2403202"},{"key":"2019111711032620100_REF23","unstructured":"Linke B, Pyttlich J, Tiemann M, et al. Identification and structural analysis of rearranged immunoglobulin heavy chain genes in lymphomas and leukemias. Leukemia.1995;9: 840-847."},{"key":"2019111711032620100_REF24","unstructured":"Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard risk acute lymphoblastic leukemia. Blood. Prepublished on September 29, 2005, as DOI 10.1182\/blood-2005-07-2708."},{"key":"2019111711032620100_REF25","doi-asserted-by":"crossref","unstructured":"Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific Taq-Man probes. Leukemia.1998;12: 2006-2014.","DOI":"10.1038\/sj.leu.2401246"},{"key":"2019111711032620100_REF26","doi-asserted-by":"crossref","unstructured":"Akaike H. A new look at statistical model identification. IEEE Trans Automat Contr.1974;19: 716-723.","DOI":"10.1109\/TAC.1974.1100705"},{"key":"2019111711032620100_REF27","doi-asserted-by":"crossref","unstructured":"Milpied N, Gaillard F, Moreau P, et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant.1998;22: 645-650.","DOI":"10.1038\/sj.bmt.1701400"},{"key":"2019111711032620100_REF28","doi-asserted-by":"crossref","unstructured":"Gribben JG, Neuberg D, Barber M, et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood.1994;83: 3800-3807.","DOI":"10.1182\/blood.V83.12.3800.3800"},{"key":"2019111711032620100_REF29","doi-asserted-by":"crossref","unstructured":"Leonard BM, Hetu F, Busque L, et al. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood.1998;91: 331-339.","DOI":"10.1182\/blood.V91.1.331"},{"key":"2019111711032620100_REF30","doi-asserted-by":"crossref","unstructured":"Rambaldi A, Carlotti E, Oldani E, et al. Quantitative PCR of bone marrow BCL2\/IgH positive cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin's lymphoma. Blood.2005;105: 3428-3433.","DOI":"10.1182\/blood-2004-06-2490"},{"key":"2019111711032620100_REF31","doi-asserted-by":"crossref","unstructured":"Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol.1998;16: 13-18.","DOI":"10.1200\/JCO.1998.16.1.13"},{"key":"2019111711032620100_REF32","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell.2003;3: 185-197.","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"2019111711032620100_REF33","doi-asserted-by":"crossref","unstructured":"Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood.2000;96: 864-869.","DOI":"10.1182\/blood.V96.3.864"},{"key":"2019111711032620100_REF34","doi-asserted-by":"crossref","unstructured":"Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood.2003;102: 749-755.","DOI":"10.1182\/blood-2002-08-2476"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/6\/2271\/1286405\/zh800606002271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/6\/2271\/1286405\/zh800606002271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T11:03:45Z","timestamp":1573988625000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/6\/2271\/22061\/Quantitative-assessment-of-molecular-remission"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,15]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,3,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-07-2845","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,15]]}}}